Gland Pharma Q4 FY26 Revenue Up 22% YoY

Gland Pharma reported Q4 FY26 revenue of INR17,428 million, a 22% YoY growth, with adjusted EBITDA at INR5,244 million (30% margin).
Full-year FY26 revenue reached INR64,307 million (14.5% growth), with CDMO business contributing 46% of total revenues and growing 28%.
Cenexi subsidiary delivered EUR45 million revenue in Q4 (4% growth) and achieved EBITDA positivity, with mid-teen EBITDA target for medium term.
Management provided FY27 guidance of 12-13% constant currency growth, excluding potential GLP-1 upside, with planned capex of INR500 crores.